Alira Health

Alira Health Extends Global Market Access Capabilities Through Acquisition of Wellmera

Expanded market access expertise strengthens Alira Health’s suite of healthcare advisory services

 

News
Published on:
December 17, 2019

FRAMINGHAM, MA, USA – December 17, 2019 – Alira Health, a leading international healthcare and life sciences advisory firm, announced that it has acquired Wellmera, a healthcare consulting firm headquartered in Basel, Switzerland specializing in market access for the pharmaceutical and biotechnology industries. The acquisition will bring global expertise in market access, pricing and reimbursement, health economics, and real-world evidence to Alira Health’s suite of healthcare advisory services.

The collective organization will advance Alira Health’s mission of enabling healthcare transformation by supporting clients across their product and corporate life cycles, with services in product development, regulatory, clinical, strategic consulting, and transaction advisory. The Wellmera team brings a wealth of experience in helping clients develop evidence, devise pricing and market access approaches, and provide tailored strategies to local client affiliates in preparation for pricing and reimbursement negotiations around the world, with a focus on European markets.

We are thrilled to welcome Wellmera and their incredible team to Alira Health. This acquisition is an important step in achieving our vision of offering a full continuum of services, particularly in the critical areas of regulatory, clinical and market access,” said Gabriele Brambilla, CEO of Alira Health. “These expanded services will help us to deliver even greater value to our clients as they develop and bring to market the next generation of healthcare innovations.

The Wellmera team is excited to join Alira Health,” says Jean-François Ricci, PharmD PhD, President and Principal at Wellmera. “This partnership allows us to bring our market access expertise to a larger global organization, helping us to impact patient care on an even greater scale. We see many synergies with Alira Health’s lifecycle approach, and feel a strong connection in our passion for healthcare, our quality of work, and the culture of our teams.”

Jean-François Ricci will become Executive Vice President of Market Access and will lead Alira Health’s Market Access practice, covering pharma, biotech, and digital health in Europe and the United States.

About Wellmera:

Wellmera is a dynamic international consulting firm focused on market access, pricing and reimbursement, health economics, and real-world evidence. We help life sciences companies demonstrate value, optimize patient access, and realize the commercial opportunity for their products throughout the lifecycle.

Wellmera was established in 2011 in Basel, Switzerland and expanded in early 2018 to the US with offices in Cambridge, MA, and San Francisco, CA, leveraging synergies for global clients between Europe and the US.

To learn more about Alira Health's Market Access practice

Click here

Related news

Webinars March 28, 2025
How Sustainability and Health Equity Are Reshaping Market Access Policy in Europe
This webinar will explore sustainability and health equity impact on reimbursement and procurement decisions in Europe and provide practical insights on how companies can adapt to the new landscape.
EU Market Access Sustainability
Case Studies March 20, 2025
Pharma Company Defines Advocacy Strategy Through Data-Driven Patient Association Mapping
Alira Health mapped 253 CVRM patient advocacy groups across 11 countries, delivering a data-driven strategy to optimize partnerships, advocacy efforts, and differentiation.
Patient Advocacy Patient Engagement Pharma
Case Studies March 6, 2025
Rare Disease Pharma Maps Rare Cholestatic Liver Disease Journey for Targeted Patient Engagement
A global pharmaceutical company specializing in rare diseases, oncology, and neuroscience sought to analyze the patient journey for progressive familial intrahepatic cholestasis (PFIC).
Patient Centricity Pharma Rare Disease
Articles March 6, 2025
ATMPs: Access, Pricing, and Ethical Issues in Perspective
Start reading this sneak peek of our recent analysis of access, pricing and ethical issues for advanced therapies medicinal products.
Advanced Therapies Market Access Orphan Drug Pricing
Articles February 17, 2025
Sustainable Pricing: An Opportunity to Improve Patient Access
Discover key pricing strategies to improve pharmaceutical health equity and price sustainability.
Market Access Pricing Sustainability
Articles February 17, 2025
Rethinking Rare Disease Development: An Integrated, Patient Access-Driven Approach
Explore how biotech companies can succeed in rare disease by integrating development, commercialization, and patient access.
Patient Centricity Pharma Rare Disease
Articles February 11, 2025
From Diagnosis to Long-Term Care: Navigating the Rare Disease Journey
For Rare Disease Day, we spoke with patient engagement expert Luca Trentin on challenges faced by rare disease patients and how pharma can better understand their needs.
Patient Centricity Pharma Rare Disease
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.